The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Research Into Causes of Systemic Vasculitis May Lead to Targeted Treatments Say Rheumatologists at the 2013 ACR/ARHP Annual Meeting

Research Into Causes of Systemic Vasculitis May Lead to Targeted Treatments Say Rheumatologists at the 2013 ACR/ARHP Annual Meeting

March 1, 2014 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • Evolutionary Medicine Provides Insight into the Chronic Inflammatory State Note Rheumatologists at the 2013 ACR/ARHP Annual Meeting
  • ACR/ARHP Annual Scientific Meeting Plenary Highlights Targets and Treatments for Several Diseases
  • ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
Explore This Issue
March 2014
Also By This Author
  • Recent Trials Investigated Targeted Therapies for Systemic Sclerosis
2013 ACR/ARHP Annual Meeting: The Roots of Vasculitis

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

SAN DIEGO—Over the past few years, a better understanding of the pathogenesis of small- and large-vessel vasculitis has emerged from a clearer picture of the role of the adaptive and innate immune system on disease development, as well a better understanding of the genetic and environmental elements that create conditions conducive for disease development.

Recent advances in the pathogenesis of small- and large-vessel vasculitis were the focus of a session at the 2013 ACR/ARHP Annual Meeting during a session titled, “Novel Insight Into the Pathogenesis of Systemic Vasculitis.” [Editor’s Note: This session was recorded and is available via ACR SessionSelect at www.rheumatology.org.]

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

New Disease Model

Cornelia M. Weyand, MD, PhD, chief of the division of immunology and rheumatology and professor of medicine at Stanford School of Medicine in Stanford, Calif., focused on giant-cell arteritis (GCA) when presenting a new disease model of large-vessel vasculitis that includes two different pathways involved in the pathogenesis of disease. Chronic inflammation ends up as a “cytokine soup,” she said, but emphasized the importance of identifying the initial event that caused the inflammation to potentially better target treatment.

Although Dr. Weyand said that multiple gaps in knowledge still exist in understanding this pathogenesis, a major clue to a better understanding is the fact that age is the strongest risk factor. She reviewed the aging immune system, focusing on two pathways of pathogenesis of GCA based on clusters of cytokines found in the tissue lesions of patients with GCA: 1) a cluster of interleukin (IL) 12, interferon (INF) gamma, and IL-2; and 2) a cluster of IL-6 and IL-17. Based on this finding, she said a new disease model of large vessel vasculitis proposes that there are two disease-relevant T-cell lineages driving vasculitis: IL-17–producing Th17 cells and INF gamma–producing TH1 cells.

Of these two T-cell lineages, the INF gamma–producing cells (Th1) comprise 20%–30% of the cells in the blood of patients with GCA. This is 10 times as many cells as the Th17, which only comprise 2%–3% of cells. “The Th17 pathway may help light the fire,” Dr. Weyand said, “but does very little in maintaining disease over time.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The importance of this for treatment is highlighted by the fact that IL 17–producing cells (Th17) are affected by corticosteroid treatment, but that INF gamma–producing cells (Th1) are not.

Summarizing her findings, Dr. Weyand described this new disease model as the triple-hit model:

  1. The vascular wall plays a role by sending and receiving signals.
  2. The cytokines IL-6 and IL-17 drive an immune pathway that is easily controlled by corticosteroid therapy and is possibly dispensable for vasculitis.
  3. The cytokines IL-12 and INF gamma drive an immune pathway that is indispensible for vasculitis and relatively resistant to steroids.

Rula A. Hajj-Ali, MD, a physician in the department of rheumatic and immunologic diseases at the Cleveland Clinic in Cleveland, Ohio, who moderated the session, emphasized that one of the challenges remaining is how to meet the diversity of pathogenesis with multiple therapies, but without overtreatment.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Vasculitis Tagged With: ACR/ARHP Annual Meeting, ANCA vasculitis, Cause, Giant Cell Arteritis, patient care, Research, rheumatologist, rheumatology, Systemic Vasculitis, VasculitisIssue: March 2014

You Might Also Like:
  • Evolutionary Medicine Provides Insight into the Chronic Inflammatory State Note Rheumatologists at the 2013 ACR/ARHP Annual Meeting
  • ACR/ARHP Annual Scientific Meeting Plenary Highlights Targets and Treatments for Several Diseases
  • ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
  • 2013 ACR/ARHP Annual Meeting: Research Provides Insight into Preclinical Rheumatic Disease

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.